What is William Blair’s Estimate for Medtronic Q3 Earnings?

Medtronic plc (NYSE:MDT) – Research analysts at William Blair issued their Q3 2027 earnings per share estimates for Medtronic in a report released on Wednesday, May 21st. William Blair analyst M. Andrew anticipates that the medical technology company will earn $1.46 per share for the quarter. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share.

A number of other analysts have also recently weighed in on MDT. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday. Truist Financial lowered their target price on Medtronic from $93.00 to $90.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Monday, May 19th. Citigroup upgraded Medtronic from a “neutral” rating to a “buy” rating and raised their target price for the company from $92.00 to $107.00 in a research report on Tuesday, March 4th. Finally, UBS Group raised their target price on Medtronic from $85.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Medtronic presently has a consensus rating of “Hold” and a consensus target price of $96.07.

Medtronic Stock Down 0.3%

Shares of Medtronic stock opened at $80.70 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.39 and a debt-to-equity ratio of 0.48. The business’s 50 day simple moving average is $85.06 and its 200-day simple moving average is $86.40. The stock has a market capitalization of $103.51 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 2.22 and a beta of 0.81. Medtronic has a twelve month low of $75.96 and a twelve month high of $96.25.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.04. The business had revenue of $8.93 billion for the quarter, compared to analysts’ expectations of $8.81 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 EPS.

Medtronic Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, June 27th. This is a boost from Medtronic’s previous quarterly dividend of $0.70. This represents a $2.84 annualized dividend and a dividend yield of 3.52%. Medtronic’s dividend payout ratio (DPR) is 85.11%.

Hedge Funds Weigh In On Medtronic

Several hedge funds have recently modified their holdings of MDT. Mainstream Capital Management LLC acquired a new position in shares of Medtronic during the 4th quarter valued at $26,000. Burkett Financial Services LLC boosted its stake in shares of Medtronic by 185.0% during the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 185 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Medtronic during the 1st quarter worth $26,000. Stephens Consulting LLC boosted its stake in shares of Medtronic by 145.7% during the 4th quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 204 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its stake in shares of Medtronic by 753.8% during the 4th quarter. Rakuten Securities Inc. now owns 333 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 294 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.